Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic InSync ICD Gains Panel Support In Tiebreaking 6-5 Vote

This article was originally published in The Gray Sheet

Executive Summary

The recommended post-market requirement for Medtronic's InSync ICD and its pacing counterpart suggests that companies that conduct pivotal studies with a small number of patients will be expected to follow up with a large trial

You may also be interested in...



JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies

An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology

JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies

An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology

“Underpowered” Trials Unethical Unless In Early Phase Or Meta-Study – JAMA

Early-phase, "underpowered" clinical trials of devices or drugs can be considered ethical only if designed to guide later pivotal studies, Scott Halpern, University of Pennsylvania School of Medicine, et al., write in the July 17 Journal of the American Medical Association

Related Content

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel